CIK 0001438533 · Large accelerated filer
Travere Therapeutics, Inc.
Sign in to watch- Ticker
- TVTX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- CA
- Entity type
- operating
- EIN
- 262383102
- Phone
- 888-969-7879
- Business address
- 3611 VALLEY CENTRE DR, SUITE 300, SAN DIEGO, CA, 92130
- Former names
- Retrophin, Inc., Desert Gateway, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $80,128,453
- in 11 filings, $80.1M under 10b5-1 plans
Net −$80,128,453. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
- Dube Eric M −$38.5M CHIEF EXECUTIVE OFFICER sold 60% of stake
- Heerma Peter −$17.9M EVP, CHIEF COMMERCIAL OFFICER sold 71% of stake
- ROTE WILLIAM E. −$13.1M Chief Research Officer sold 68% of stake
- Cline Christopher R. −$3.2M CHIEF FINANCIAL OFFICER sold 37% of stake
- Inrig Jula −$2.8M EVP, Head of R&D & CMO sold 31% of stake
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-05-19 | Squarer Ron Director | Grant or award | +4,000 | 39,375 | ||
| 2026-05-19 | Squarer Ron Director | Grant or award · Stock option (right to buy) | +12,000 | 12,000 | ||
| 2026-05-19 | Coughlin Timothy Director | Grant or award | +4,000 | 56,250 | ||
| 2026-05-19 | Coughlin Timothy Director | Grant or award · Stock option (right to buy) | +12,000 | 12,000 | ||
| 2026-05-19 | Williams Brinkley Ruth Director | Grant or award | +4,000 | 29,750 | ||
| 2026-05-19 | Williams Brinkley Ruth Director | Grant or award · Stock option (right to buy) | +12,000 | 12,000 | ||
| 2026-05-19 | LYONS GARY A Director | Grant or award | +4,000 | 61,500 | ||
| 2026-05-19 | LYONS GARY A Director | Grant or award · Stock option (right to buy) | +12,000 | 12,000 | ||
| 2026-05-15 | Coughlin Timothy Director | Sale 10b5-1 | −3,250 | $43.49 | $141K | 52,250 |
| 2026-05-06 | Cline Christopher R. CHIEF FINANCIAL OFFICER | Sale 10b5-1 | −310 | $43.95 | $14K | 118,658 |
| 2026-05-06 | Inrig Jula CHIEF MEDICAL OFFICER | Sale 10b5-1 | −311 | $43.95 | $14K | 113,238 |
| 2026-05-06 | Dube Eric M CHIEF EXECUTIVE OFFICER | Sale 10b5-1 | −22,500 | $43.95 | $989K | 432,886 |
| 2026-05-06 | ROTE WILLIAM E. Chief Research Officer | Sale 10b5-1 | −2,763 | $43.95 | $121K | 115,474 |
| 2026-05-06 | REED ELIZABETH E Chief Legal Officer and GC | Sale 10b5-1 | −2,076 | $43.95 | $91K | 105,211 |
| 2026-05-05 | Cline Christopher R. CHIEF FINANCIAL OFFICER | Sale 10b5-1 | −2,181 | $46.65 | $102K | 118,968 |
| 2026-05-05 | Inrig Jula CHIEF MEDICAL OFFICER | Sale 10b5-1 | −2,174 | $46.65 | $101K | 113,549 |
| 2026-05-05 | Heerma Peter CHIEF COMMERCIAL OFFICER | Sale | −2,174 | $46.65 | $101K | 140,684 |
| 2026-05-05 | Baynes Roy D. Director | Option exercise 10b5-1 | +4,500 | $18.27 | $82K | 42,000 |
| 2026-05-05 | Baynes Roy D. Director | Sale 10b5-1 | −4,500 | $46.65 | $210K | 37,500 |
| 2026-05-05 | Baynes Roy D. Director | Option exercise · Stock option (right to buy) 10b5-1 | −4,500 | 0 |
Page 7 of 41 · 802 trades